Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03521908 · ClinicalTrials.gov registry record
A Study to Compare the Risk of a Major Bleeding in Participants Who Received Blood Thinning Medications Following a Blood Clot
A clinical trial of Venous Thromboembolism (VTE), sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- 35,756
- Enrollment target
- 1
- Study location
NCT03521908 is a study of Venous Thromboembolism (VTE) that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 35,756 participants, above the 3,520-participant average among 3 other Venous Thromboembolism (VTE) trials with a reported enrollment target (916% higher). The trial reports 1 study location across 1 state.
The verdict
NCT03521908, a study of Venous Thromboembolism (VTE), has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- 35,756 participants
- Enrollment target
- 1
- Study location
Study Summary
A study to compare the risk of a major bleeding in participants who received 2 different blood thinning medications following a blood clot
Conditions Studied
Study Locations (1)
New Jersey
- Local Institution - Princeton
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35,756 participants |
| Start Date | 2016-06-13 |
| Est. Completion | 2018-11-23 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03521908
The ClinicalTrials.gov registry entry for NCT03521908 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 35,756 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 3,520-participant average among 3 other Venous Thromboembolism (VTE) trials with a reported enrollment target (916% higher). The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Venous Thromboembolism (VTE) appearing as the primary indexed condition, and to 0 interventions.
NCT03521908 reports 1 study location spanning 1 distinct geographic area - top geographies include New Jersey.
Frequently Asked Questions
What is clinical trial NCT03521908 about?
NCT03521908 is a clinical study titled "A Study to Compare the Risk of a Major Bleeding in Participants Who Received Blood Thinning Medications Following a Blood Clot". A study to compare the risk of a major bleeding in participants who received 2 different blood thinning medications following a blood clot
What is the current status of trial NCT03521908?
This trial is currently completed. The enrollment target is 35,756 participants. The study started on 2016-06-13. Estimated completion is 2018-11-23.
What conditions does trial NCT03521908 study?
This clinical trial studies the following conditions: Venous Thromboembolism (VTE).
Who is sponsoring clinical trial NCT03521908?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03521908 being conducted?
This trial has 1 study location across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Venous Thromboembolism (VTE)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.